Uncategorized

Celleron Therapeutics and Argonaut Therapeutics Announce Completion of Merger to Form IngenOx Therapeutics

Jan 5, 2023

Oxford, UK – 5 January 2023 Celleron Therapeutics and Argonaut Therapeutics have jointly announced today the completion of a merger

Celleron Therapeutics founder David Kerr CBE receives major Chinese award

Nov 8, 2022

Oxford, UK, 08 Nov 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today that

Celleron Therapeutics Co-founder Professor David Kerr awarded Fellowship of ESMO

Sep 22, 2022

Oxford, UK, 22 Sep 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today that

Celleron Therapeutics partnered programme receives funding for investigating zabadinostat in immune checkpoint inhibitor resistant liver cancer

Aug 15, 2022

Oxford, UK, 15 August 2022 – Celleron Therapeutics, the UK-based company developing innovative precision cancer medicines, announces today that in

Celleron Therapeutics reports 3-year survival data from Phase II clinical trial in MSS colorectal cancer patients treated with zabadinostat and nivolumab combination

Jun 29, 2022

Oxford, UK, 29 June 2022 – Celleron Therapeutics, the UK-based company developing innovative precision cancer medicines, announced today a 3-year

Celleron Therapeutics reports over 2-year survival of cancer patient treated with zabadinostat monotherapy

Apr 7, 2022

Oxford, UK, 7 April 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today a

Celleron Therapeutics Deploys a Digital Pathology Biomarker Platform in Pivotal Colorectal Cancer Clinical Study

Nov 30, 2021

Oxford, UK, 30 November 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the adoption

Celleron Therapeutics Appoints Corporate Governance Expert, Katherine Innes Ker, To Board

Nov 8, 2021

Oxford, UK, 8 November 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the

Celleron Therapeutics appoints global financier Richard Taylor as new Board Director

Sep 27, 2021

Oxford, UK, 27th Sep 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the

Celleron Therapeutics’ CXD101 shows promising clinical results in its China IND programme with partner Nuance Biotech

Jul 6, 2021

Oxford, UK, 6th July 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced encouraging early